Reviva Pharmaceuticals Holdings, Inc. financial data

Symbol
RVPH, RVPHW on Nasdaq
Industry
Pharmaceutical Preparations
Location
10080 N Wolfe Road, Suite Sw3 200, Cupertino, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Tenzing Acquisition Corp. (to 12/14/2020)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -631 % -937%
Return On Assets -293 % -102%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.9 M shares +36.5%
Common Stock, Shares, Outstanding 27.9 M shares +36.5%
Entity Public Float 104 M USD
Common Stock, Value, Issued 2.79 K USD +36.5%
Weighted Average Number of Shares Outstanding, Basic 29.9 M shares +36.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.7 M USD +40.8%
General and Administrative Expense 8.72 M USD +66.5%
Operating Income (Loss) -40.4 M USD -45.7%
Nonoperating Income (Expense) 620 K USD +1655%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.8 M USD -43.6%
Income Tax Expense (Benefit) 21.4 K USD +6.17%
Net Income (Loss) Attributable to Parent -39.8 M USD -43.6%
Earnings Per Share, Basic -1.59 USD/shares -16.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12 M USD +6.38%
Assets 13.5 M USD +4.61%
Accounts Payable, Current 5.72 M USD +100%
Employee-related Liabilities, Current 1.22 M USD
Liabilities, Current 14.5 M USD +35%
Liabilities 14.8 M USD +31.5%
Retained Earnings (Accumulated Deficit) -142 M USD -39.1%
Stockholders' Equity Attributable to Parent -1.35 M USD -183%
Liabilities and Equity 13.5 M USD +4.61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.7 M USD -47.5%
Net Cash Provided by (Used in) Financing Activities 332 K USD -51.7%
Common Stock, Shares Authorized 115 M shares 0%
Common Stock, Shares, Issued 27.9 M shares +36.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.49 K USD
Deferred Tax Assets, Valuation Allowance 27.5 M USD +58.7%
Deferred Tax Assets, Gross 27.5 M USD +58.7%
Depreciation 0 USD
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 15.3 M USD +20.2%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 16.9 K USD -18.4%
Preferred Stock, Shares Authorized 10 M shares
Additional Paid in Capital 140 M USD +35.6%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 2.4 K USD -74.1%
Current Federal Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.73 M USD +1878%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 3.49 K USD -54.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares